Frankfurt
11.11.26 | 09:55
28,400 Euro
+0,71 % +0,200
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 28,000 | 29,200 | 10:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.10. | Nanobiotix-Aktie legt nach positiven Melanom-Studiendaten zu | 6 | Investing.com Deutsch | ||
| 24.10. | Nanobiotix S.A.: NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma | 7 | GlobeNewswire (USA) | ||
| 20.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.10. | Nanobiotix names new CFO | 9 | Seeking Alpha | ||
| 01.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 01.10. | Nanobiotix S.A.: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer | 374 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 28.09. | Can J&J's Partnership Drive More Upside for Nanobiotix? | 11 | Insider Monkey | ||
| 24.09. | Nanobiotix GAAP EPS of -€0.70, revenue of €5.6M | 3 | Seeking Alpha | ||
| 24.09. | Nanobiotix S.A.: NANOBIOTIX Provides First Half 2026 Operational and Financial Update | 764 | GlobeNewswire (Europe) | Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally... ► Artikel lesen | |
| 22.09. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 22.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.09. | Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug | 5 | Investing.com | ||
| 14.09. | Nanobiotix S.A.: NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer | 590 | GlobeNewswire (Europe) | All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was... ► Artikel lesen | |
| 09.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 25.08. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 25.08. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 9 | SEC Filings | ||
| 30.07. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 08.06. | Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans | 5 | SEC Filings |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 6,980 | 0,00 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| COSCIENS BIOPHARMA | 5,200 | 0,00 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 92,22 | -0,04 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer | Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 11,540 | +3,22 % | AbCellera becomes latest biotech to abandon dream of developing OX40 drug | ||
| GLOW LIFETECH | 0,016 | -13,51 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 344,20 | -0,64 % | Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,110 | -10,48 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,138 | -0,28 % | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | ||
| WHITEHAWK THERAPEUTICS | 2,700 | -0,74 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights | On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 10,110 | +1,00 % | Innovent Biologics: Innovent Announces Phase 3 RESTORE-3 Study of SYCUME (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease | SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive... ► Artikel lesen | |
| GEOVAX LABS | 0,111 | -0,18 % | EQS-News: GeoVax, Inc.: GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement 09.11.2026 / 14:30 CET/CEST
The... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,520 | +0,80 % | Ovid Therapeutics GAAP EPS of -$0.10 misses by $0.02 | ||
| COCRYSTAL | 0,900 | -5,76 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 8,300 | -2,35 % | Precision BioSciences announces $125M public offering; shares up |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,71 % bei einem Aktienkurs von 28,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.